{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Bio-Rad Laboratories, Inc.
Is Bio-Rad Laboratories, Inc. overvalued or undervalued?
As of October 17, 2025, Bio-Rad Laboratories, Inc. is considered fairly valued with a P/E ratio of 5 and a significant discount compared to peers, but its stock has underperformed the S&P 500 with a year-to-date return of -5.63% and a five-year return of -44.30%.
Bio-Rad Laboratories Experiences Valuation Adjustment Amid Competitive Market Landscape
Bio-Rad Laboratories, Inc. has recently adjusted its valuation, reporting a P/E ratio of 5 and a low PEG ratio of 0.07. Its performance indicators reveal a year-to-date return of -5.63%, contrasting with the S&P 500's gain, underscoring the challenges in a competitive Pharmaceuticals & Biotechnology sector.
Is Bio-Rad Laboratories, Inc. overvalued or undervalued?
As of October 17, 2025, Bio-Rad Laboratories, Inc. is fairly valued with a P/E ratio of 16.20, lower than its peers, but has underperformed year-to-date with a return of -5.63% compared to the S&P 500's 13.30%.
Bio-Rad Laboratories, Inc. Announces Revision in Stock Evaluation Amid Market Volatility
Bio-Rad Laboratories, Inc. has recently seen a revision in its evaluation, with its stock price at $271.36. The company has faced notable volatility over the past year, with a high of $387.99 and a low of $211.43, while its performance has lagged behind the S&P 500.
Bio-Rad Laboratories Forms Golden Cross, Signaling Potential Bullish Breakout
Bio-Rad Laboratories, Inc. has recently experienced a Golden Cross, indicating a potential shift in momentum. Current technical indicators present a mixed outlook, with bullish signals on daily and weekly moving averages. However, the stock has underperformed over the past year, raising caution among investors regarding its future performance.
Is Bio-Rad Laboratories, Inc. technically bullish or bearish?
As of August 25, 2025, Bio-Rad Laboratories, Inc. shows a mildly bearish trend with mixed technical indicators, underperforming the S&P 500 with a year-to-date return of -12.79% compared to the benchmark's 12.22%.
Is Bio-Rad Laboratories, Inc. overvalued or undervalued?
As of August 22, 2025, Bio-Rad Laboratories, Inc. is fairly valued with a P/E ratio of 5 and is trading at a significant discount compared to peers, but has underperformed the S&P 500 with a year-to-date return of -12.79% and a three-year decline of -36.13%.
Is Bio-Rad Laboratories, Inc. technically bullish or bearish?
As of June 18, 2025, the trend is mildly bearish due to daily moving averages indicating bearish momentum, despite some mildly bullish signals from the weekly MACD and KST, while the monthly MACD and weekly Bollinger Bands remain bearish.
Is Bio-Rad Laboratories, Inc. overvalued or undervalued?
As of April 28, 2022, Bio-Rad Laboratories, Inc. is considered overvalued and risky, with a P/E ratio of 5, an EV to EBITDA of 10.62, and a year-to-date stock decline of 28.30%, significantly underperforming compared to its industry peers.
Who are in the management team of Bio-Rad Laboratories, Inc.?
As of March 2022, the management team of Bio-Rad Laboratories, Inc. includes Norman Schwartz (Chairman, President, CEO), Gregory Hinckley (Lead Independent Director), Alice Schwartz, Jeffrey Edwards, Melinda Litherland, and Arnold Pinkston (all Independent Directors).
What does Bio-Rad Laboratories, Inc. do?
Bio-Rad Laboratories, Inc. manufactures products for life science research, healthcare, and analytical chemistry, with a market cap of approximately $6.34 billion. As of March 2025, it reported net sales of $585 million and a net profit of $64 million.
How big is Bio-Rad Laboratories, Inc.?
As of Jun 18, Bio-Rad Laboratories, Inc. has a market capitalization of $6.34 billion, with net sales of $2.54 billion and a net profit of -$2.16 billion over the latest four quarters.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
